Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

Clinical trial NCT07650240 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07650240
Sponsor: Mayo Clinic
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Prostate Adenocarcinoma Stage IVB Prostate Cancer AJCC v8 Castration-Sensitive Prostate Cancer Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Prostate Cancer Prostate Adenocarcinoma Adenocarcinoma of the Prostate Localized Prostate Carcinoma Metastatic Prostate Cancer Metastatic Prostate Adenocarcinoma Advanced Prostate Cancer Advanced Prostate Adenocarcinoma

Start date: 2026-07-01
Primary completion: 2030-12-30
Enrollment: 202

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.